Why the study?
Does adjusted-dose prasugrel compared with clopidogrel improve ischemic events and safety in Japanese patients with Acute Coronary Syndrome?
Does adjusted-dose prasugrel compared with clopidogrel improve ischemic events and safety in Japanese patients with Acute Coronary Syndrome?
Adjusted-dose prasugrel (20/3.75 mg) demonstrates a favorable efficacy and safety profile in Japanese patients with ACS.
Supports adjusted-dose prasugrel in Japanese ACS; leaves open randomized confirmation versus clopidogrel.
Prasugrel 20/3.75 mg was associated with a low incidence of ischemic events, similar to the results of TRITON-TIMI 38, and with a low risk of clinically serious bleeding in Japanese ACS patients.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: